KR102137290B1 - 최적화된 피하 치료약 - Google Patents

최적화된 피하 치료약 Download PDF

Info

Publication number
KR102137290B1
KR102137290B1 KR1020147031042A KR20147031042A KR102137290B1 KR 102137290 B1 KR102137290 B1 KR 102137290B1 KR 1020147031042 A KR1020147031042 A KR 1020147031042A KR 20147031042 A KR20147031042 A KR 20147031042A KR 102137290 B1 KR102137290 B1 KR 102137290B1
Authority
KR
South Korea
Prior art keywords
factor
delete delete
blood
subcutaneous
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147031042A
Other languages
English (en)
Korean (ko)
Other versions
KR20140146171A (ko
Inventor
윌리엄 헨리
리처드 울프- 개러웨이
존 찰스 마요
마이클 제임스 얼
Original Assignee
캔탭 바이오팔마수티칼 패턴트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by 캔탭 바이오팔마수티칼 패턴트 리미티드 filed Critical 캔탭 바이오팔마수티칼 패턴트 리미티드
Publication of KR20140146171A publication Critical patent/KR20140146171A/ko
Application granted granted Critical
Publication of KR102137290B1 publication Critical patent/KR102137290B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020147031042A 2012-04-16 2013-04-16 최적화된 피하 치료약 Active KR102137290B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1206628.8 2012-04-16
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GB1213712.1 2012-08-01
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GB1214985.2 2012-08-22
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Publications (2)

Publication Number Publication Date
KR20140146171A KR20140146171A (ko) 2014-12-24
KR102137290B1 true KR102137290B1 (ko) 2020-07-23

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147031042A Active KR102137290B1 (ko) 2012-04-16 2013-04-16 최적화된 피하 치료약

Country Status (29)

Country Link
US (2) US20150086524A1 (enExample)
EP (1) EP2838566A2 (enExample)
JP (3) JP2015512927A (enExample)
KR (1) KR102137290B1 (enExample)
CN (1) CN104411335A (enExample)
AP (1) AP2014008049A0 (enExample)
AU (3) AU2013248296A1 (enExample)
BR (1) BR112014025737A2 (enExample)
CA (1) CA2869993C (enExample)
CL (1) CL2014002773A1 (enExample)
CO (1) CO7151496A2 (enExample)
CR (1) CR20140475A (enExample)
EA (1) EA033469B1 (enExample)
EC (1) ECSP14023048A (enExample)
GB (3) GB201910184D0 (enExample)
GE (1) GEP201706716B (enExample)
HK (1) HK1200695A1 (enExample)
IL (1) IL235129B (enExample)
IN (1) IN2014DN08598A (enExample)
MD (1) MD20140123A2 (enExample)
MX (2) MX2014012512A (enExample)
MY (1) MY190257A (enExample)
NI (1) NI201400122A (enExample)
NZ (1) NZ701205A (enExample)
PE (1) PE20150226A1 (enExample)
PH (1) PH12014502314B1 (enExample)
SG (1) SG11201406492YA (enExample)
WO (1) WO2013156488A2 (enExample)
ZA (1) ZA201407370B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104073482A (zh) * 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP3307237A1 (en) * 2015-06-12 2018-04-18 Laboratoire Français du Fractionnement et des Biotechnologies Injectable composition of factor vii and fillers
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
CN109998994B (zh) * 2018-02-13 2021-12-07 四川大学 包含药物的柔性脂质体及其制备方法
CN114929261A (zh) 2020-02-17 2022-08-19 生物测试股份公司 凝血因子viii的皮下施用
CN115443147A (zh) * 2020-04-23 2022-12-06 伊莱利利公司 抗体的皮下吸收和生物利用度

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (enExample) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
JP3866279B2 (ja) 1992-09-28 2007-01-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド ペプチド連結用の新規な試薬
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2177644A1 (en) * 1995-05-31 1996-12-01 Peter D. Senter Polymeric prodrugs for beta-lactamase and uses thereof
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
AU2605099A (en) * 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1280548B1 (en) 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor VII
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
KR101186140B1 (ko) * 2002-06-21 2012-09-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페길화된 인자 ｖｉｉ 글리코형태
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ATE431150T1 (de) 2004-03-04 2009-05-15 Eisai R&D Man Co Ltd Zusammensetzung mit benzamidin-derivat und verfahren zur stabilisierung von benzamidin- derivat
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
JP2008507990A (ja) 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
AU2006280932A1 (en) * 2005-08-19 2007-02-22 Novo Nordisk A/S Glycopegylated factor VII and factor Vila
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
AU2007340382B2 (en) * 2006-12-27 2013-06-27 Nektar Therapeutics Von Willebrand Factor- and Factor VIII-polymer conjugates having a releasable linkage
US20100143326A1 (en) 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
EP2209494B1 (en) 2007-10-09 2016-07-20 Polytherics Limited Novel conjugated proteins and peptides
EP2586794A3 (en) 2007-10-16 2013-07-17 Pharmacyclics, Inc. Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CA2721362A1 (en) * 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
EP2285401A1 (en) * 2008-05-23 2011-02-23 Novo Nordisk Health Care AG Low viscosity compositions comprising a pegylated gla-domain containing protein
US8969626B2 (en) 2008-07-21 2015-03-03 Polytherics Limited Reagents and method for conjugating biological molecules
US8143347B2 (en) * 2008-10-15 2012-03-27 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
MX2011004085A (es) * 2008-10-17 2011-09-27 Baxter International Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
RU2595442C2 (ru) * 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
KR102325780B1 (ko) * 2010-07-30 2021-11-12 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
JP2018024684A (ja) 2018-02-15
US11351112B2 (en) 2022-06-07
MY190257A (en) 2022-04-11
PE20150226A1 (es) 2015-02-14
EA033469B1 (ru) 2019-10-31
MX2014012512A (es) 2015-01-15
WO2013156488A3 (en) 2014-01-16
JP6550107B2 (ja) 2019-07-24
AU2018200111A1 (en) 2018-01-25
GB201418864D0 (en) 2014-12-03
HK1200695A1 (en) 2015-08-14
CA2869993A1 (en) 2013-10-24
IL235129B (en) 2022-06-01
AU2013248296A1 (en) 2014-11-13
GB201910190D0 (en) 2019-08-28
SG11201406492YA (en) 2014-11-27
KR20140146171A (ko) 2014-12-24
GB2516388A (en) 2015-01-21
US20180036229A1 (en) 2018-02-08
IN2014DN08598A (enExample) 2015-05-22
NZ701205A (en) 2016-02-26
AU2018200111B2 (en) 2019-11-07
MD20140123A2 (ro) 2015-04-30
WO2013156488A2 (en) 2013-10-24
CL2014002773A1 (es) 2015-01-16
GEP201706716B (en) 2017-08-10
IL235129A0 (en) 2014-12-31
EP2838566A2 (en) 2015-02-25
BR112014025737A2 (pt) 2017-07-04
JP2015512927A (ja) 2015-04-30
AP2014008049A0 (en) 2014-11-30
JP2019131593A (ja) 2019-08-08
GB201910184D0 (en) 2019-08-28
ZA201407370B (en) 2017-09-27
NI201400122A (es) 2016-12-02
MX2020014208A (es) 2021-03-09
CO7151496A2 (es) 2014-12-29
CR20140475A (es) 2015-01-23
AU2020200842A1 (en) 2020-02-27
ECSP14023048A (es) 2015-11-30
PH12014502314B1 (en) 2020-01-31
CN104411335A (zh) 2015-03-11
CA2869993C (en) 2023-05-23
US20150086524A1 (en) 2015-03-26
PH12014502314A1 (en) 2015-01-12
EA201491702A1 (ru) 2015-03-31

Similar Documents

Publication Publication Date Title
KR102137290B1 (ko) 최적화된 피하 치료약
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
US11040109B2 (en) Blood coagulation protein conjugates
SG178141A1 (en) Blood coagulation protein conjugates

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180416

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190902

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200501

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200717

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200717

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241224

Start annual number: 5

End annual number: 5